IBO · DEFM14A

Impact BioMedical: Zoar Labs Takes Control with 93.32% Stake

Impact BioMedical's recent DEFM14A filing outlines a transformative transaction that would see Zoar Labs taking a commanding 93.32% stake in the newly formed PubCo. This move is not a merger of equals but a significant shift in control, with Impact holders left with a mere 4.80% stake. The deal values Zoar at $877.6 million, a figure that aligns with CVA's valuation range but lacks a refreshed fairness opinion post-amendments.

Ownership and Control Shift

The transaction heavily favors Zoar Labs, assigning them 167.976 million shares of PubCo. Impact holders are allocated approximately 8.64 million shares, translating to a minor 4.80% stake. This stark disparity highlights the shift in control and influence, with Zoar's shareholder dominating the ownership landscape. The filing also mentions discrepancies in post-closing ownership figures, which remain unresolved, adding uncertainty to the final ownership structure.

Financial and Operational Risks

While Zoar Labs brings substantial revenue of $651.7 million and net income of $77.7 million, its operating cash flow is a mere $0.6 million. This is dwarfed by its estimated working-capital needs of $168.7 million over the next 12 months. Impact's financial position is precarious, with only $10,000 in cash against $2.045 million in liabilities as of June 30, 2026. These figures underscore the financial strain and the importance of securing additional funding to meet closing conditions, including a net cash position of at least $10,000 and zero net debt.

Closing Conditions and Strategic Implications

The deal's completion hinges on several approvals, including SEC registration effectiveness and NYSE American listing approval. Impact's special meeting on November 13, 2026, is a critical milestone, with 85.3% of shares reportedly committed to supporting the proposals. However, the filing materials reveal inconsistencies in share-count descriptions and unresolved bridge-loan figures, which could complicate the closing process.

The strategic shift from Impact's cash-constrained operations to Zoar's larger scale is evident, but it comes with significant risks. Zoar's financial obligations, including a bridge loan and Peridot repayment, add layers of complexity. The leadership structure post-closing, with Visvanats as chairman, CEO, and interim CFO, suggests concentrated control, potentially limiting minority-holder protections.

What to Watch

| Catalyst | Why It Matters | Timeline |
|----------|----------------|----------|
| Impact stockholder vote | Determines approval of the transaction | November 13, 2026 |
| SEC registration and NYSE approval | Required for closing | Before closing |
| Closing or extension | Finalizes or delays the transaction | By November 20, 2026 |
| Zoar HK’s Peridot repayment | Affects financial stability | Through year-end 2026 |
| Reconciliation of share counts | Clarifies ownership structure | At or before closing |

This transaction represents a significant shift in control and strategy for Impact BioMedical, with Zoar Labs poised to dominate the new entity. However, financial uncertainties and unresolved discrepancies pose risks that investors must carefully consider.

[Generated on Edgar Tracker · edgartracker.com · Article · GPT 4o]